With U.S. stocks booming, North American wealthy led the way globally. And the top 1% of wealthy globally—the so-called ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...